Synova-backed Charnwood Molecular, a provider of outsourced drug discovery services supporting an international client base of pharmaceutical and biotech companies in developing novel drugs, agreed to acquire Aurelia Bioscience, a provider of pharmacological profiling and screening services. Financial terms were not disclosed. “We are proud to welcome the Aurelia Bioscience team into our company. Gary Allenby, Kathy Dodgson and their team have built an enviable reputation for scientific rigour and excellence - values that are deeply rooted in our own business culture - and this acquisition represents another key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector," Steve Allin, Charnwood Molecular CEO.